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Ascaris and Parascaris are important parasites in the family Ascarididae, large, ubiquitous intestinal-dwelling
nematodes infecting all classes of vertebrates. Parasitic nematode drug resistance in veterinary medicine and
drug recalcitrance in human medicine are increasing worldwide, with few if any new therapeutic classes on the
horizon. Some of these parasites are zoonotic, e.g., Ascaris is passed from humans to pigs and vice versa. The
development of new therapies against this family of parasites would have major implications for both human and
livestock health. Here we tested the therapeutic ability of a paraprobiotic or dead probiotic that expresses the
Bacillus thuringiensis Cry5B protein with known anthelmintic properties, against zoonotic Ascaris suum and
Parascaris spp. This paraprobiotic, known as IBaCC, intoxicated A. suum larvae in vitro and was highly effective in
vivo against intestinal A. suum infections in a new mouse model for this parasite. Fermentation was scaled up to
350 l to treat pigs and horses. Single dose Cry5B IBaCC nearly completely cleared A. suum infections in pigs.
Furthermore, single dose Cry5B IBaCC drove fecal egg counts in Parascaris-infected foals to zero, showing at least
parity with, and potential superiority to, current efficacy of anthelmintics used against this parasite. Cry5B IBaCC
therefore represents a new, paraprobiotic One Health approach towards targeting Ascarididae that is safe,
effective, massively scalable, stable, and useful in human and veterinary medicine in both the developed and
developing regions of the world.

1. Introduction

gastrointestinal nematode (GIN) parasites live in the small intestine,
reaching more than 30 cm in length. Recent nuclear genome studies
indicated that A. lumbricoides and Ascaris suum, the ubiquitous and
important Ascaris parasite of pigs, are highly interbred [3]. Indeed,
A. suum is a zoonosis that can express as a haplotype of A. lumbricoides,

Ascaris lumbricoides or the large intestinal roundworm is the most
common nematode parasite of humans, infecting approximately 1
billion people in mostly tropical and subtropical countries [1,2]. These
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with each parasite species able to infect both pigs and humans [3–8]. In
the same family (Ascarididae) and closely related to these Ascaris par
asites is Parascaris spp., the omnipresent parasite of foals and young
horses around the world that has developed multi-drug resistance, with
increasing concern [9]. Ascaris and Ascaris-related parasites are impor
tant components of the “One Health” concept [3,10,11].
Infestation in humans with Ascaris is responsible for an estimated
loss of 1–1.5 million disability adjusted life-years (DALYs) and for
60,000–200,000 deaths yearly due to obstruction of the digestive tract
and hepatobiliary and pancreatic ascariasis, the true impact of which
has likely been underestimated [1,2,12]. Infection rates can be very high
in places, e.g., reaching >50% prevalence in six states in India covering
nearly 30% of the total population of India and > 44% prevalence in a
systematic meta-analysis of studies conducted in Nigerian children
[13,14]. Acute symptoms due to adult parasites inhabiting the gastro
intestinal (GI) tract include abdominal pain, bloating, nausea, vomiting,
anorexia, and intermittent diarrhea (with heavy loads leading to serious
complications and even death). However, the more significant impact is
in children who are more susceptible to these parasites. The conse
quences of long-term infestation includes malabsorption of nutrients,
protein energy malnutrition, and reduced food intake, leading to growth
retardation, negative impacts on cognitive development, school absen
teeism, and reduced economic productivity [1,2,8,15].
Although single dose anthelmintic cure rates against A. lumbricoides
are reported to be >90% [8], there are numerous reports in the literature
of deficiencies in treating this parasite with benzimidazoles (anthel
mintic of choice for Mass Drug Administration or MDA). These diffi
culties include lower than expected cure rates with albendazole in Africa
and Asia (0%, 19%, 41%, and 56% in four separate studies; [16–19])
and strong persistence of this parasite in African, Asian, and Central
American countries despite consistent annual deworming campaigns
spanning multiple years [20–25]. Known benzimidazole resistance al
leles have been detected in natural populations of Ascaris, although
there is evidence that resistance/recalcitrance may occur without these
alleles [19,21,26]. Although ivermectin can also be used against this
parasite, annual MDA incorporating both albendazole and ivermectin
has failed to eliminate it, resulting in only modest prevalence reductions
[27].
As noted above, ascarids closely related to A. lumbricoides are also
common and important parasites of livestock and companion animals.
Ascaris suum is a common production and health problem in pigs
worldwide because of poor feed utilization and liver condemnation at
slaughter where different stringencies of management fail to eliminate
infection rates even in large global producing countries [28]. Recent
A. suum prevalence surveys in the United States are lacking but routine
deworming strategies are used in >77% of production facilities for
breeding age pigs and at >17% and > 14% for nursery and grower/
finisher pigs, respectively [29], indicating a need for practical and
effective anthelmintic formulations in the market-place. Parascaris spp.
are the most important parasites of foals and young horses around the
world [9]. The parasites are truly ubiquitous and virtually every foal
should be considered exposed. Equine ascarids cause small intestinal
impaction when a cluster of worms block the intestinal lumen. This is a
painful and life-threatening condition, and even with successful
abdominal surgery, the prognosis for long-term survival is guarded to
poor [9]. This is concerning as Parascaris spp. are found widely resistant
to currently available anthelmintic drug classes, most notably to the
most widely used drug class, the macrocyclic lactones [30]. The phar
maceutical industry has developed and introduced very few new
anthelmintic drug classes and none for equine use since the early 1980s,
and research exploring alternative treatment modalities is urgently
needed. There is real concern that Ascaris spp. could also (indepen
dently) develop widespread drug resistance that is now observed in
closely related Parascaris spp. Taken together, these findings all point to
the urgency and importance of developing new anthelmintic formula
tions for treating Ascaris and Parascaris parasites of humans, livestock,

and companion animals.
Continuing human MDA campaigns and veterinary parasite control
strategies would therefore benefit substantially with the addition of new
anthelmintics against ascarid parasites with the following requirements:
highly and broadly potent against this family of helminths, and safe,
inexpensive, and massively scalable for MDA. We have recently
described an active pharmaceutical ingredient (API) called IBaCC (see
below) containing the Bacillus thuringiensis (Bt) Crystal (Cry) protein
Cry5B that is effective against human hookworm infections in rodents
and against Haemonchus contortus infections in sheep and that meets all
the requirements for MDA [31,32]. Cry5B itself was shown to be active
against A. suum in pigs when delivered as a live spore-crystal lysate
(SCL) [33]. However, delivery of SCL or of live bacteria in general is not
ideal for MDA because of an unstable shelf life, environmental concerns,
potential safety/regulatory issues, and development of resistance via
suboptimal dosing [31,34–38]. Here, for the first time, we describe and
test Cry5B IBaCC against Ascaris infection in pigs and Cry5B itself (as
IBaCC) for the first time against Parascaris infection in horses.
2. Materials and methods
2.1. Animal ethics and approvals
All protocols in the study were approved by the University of Ken
tucky Institutional Animal Care and Use Committee (Protocol
2015–2078) for the equine studies and the USDA Beltsville - Institutional
Animal Care and Use Committee #18–008, #18–029 and #17–019 for
use of mice and pigs, respectively, and Institutional Biosafety Committee
#271.
2.2. Preparation of Cry5B IBaCC and in vitro studies
Cry5B IBaCC was prepared as described [31]. Briefly, spo0AB. thuringiensis cells expressing Cry5B from a vegetative promoter were
cultured in 3× LB for 48 h, resuspended in 1/2 volume, treated with
essential oil, and then washed. All Cry5B IBaCC used in this study was
prepared at the Synthetic Biomanufacturing Facility, Utah State Uni
versity, at a scale of 350 l. Cry5B concentration was quantitated relative
to BSA standards by SDS PAGE densitometry.
Ascaris suum fourth staged larval (L4) parasites were isolated from
the small intestines of B6/STAT6KO mice ~12 days post-inoculation (P.
I.) and shipped overnight to the Aroian laboratory from the Urban lab
oratory in Beltsville, MD. The next day, the parasites were subjected to in
vitro testing with Cry5B IBaCC at two doses and buffer control using the
same protocol for setting up and scoring Ascaris larval in vitro [33,39]. In
each experiment, each condition contained two wells with five larvae
per well. Simply, larvae that moved either on their own or upon
touching with a needle were scored as alive and larvae that failed to
move even after touching were scored as dead [33,39]. The experiment
was repeated twice with two different batches of larvae and two
different batches of Cry5B IBaCC. A separate experiment was performed
in which IBa (Inactivated Bacterium with empty vector, identical and
identically processed to IBaCC in every way except that the vector does
not contain a Cry5B insert) was matched in optical density (OD600) to
100 μg/mL IBaCC and tested against A. suum L4 parasites in two inde
pendent experiments (n = 20 larvae total). Incubation with IBa resulted
in 100% viability (20/20) of A. suum L4 up to and including 96 h
incubation.
2.3. Mouse Ascaris in vivo experiment
Breeding pairs of C57BL/6(B6)-STAT6KO were originally procured
from the Jackson Laboratories, Bar Harbor, ME and bred at the USDA/
ARS/Beltsville Agricultural Research Center in Beltsville, MD. Groups of
five mice each containing both males and females were inoculated per os
with 10,000 infective A. suum eggs and 12 days later were 1) untreated,
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2) treated per os with IBaCC containing Cry5B at 6 mg/kg body weight,
or 3) treated per os with IBaCC containing Cry5B at 20 mg/kg body
weight. Those in group 3 received a second dose of IBaCC containing
Cry5B at 20 mg/kg body weight on the next day. A. suum L4 were iso
lated from the small intestines six days later by opening the small in
testine with scissors and placing them above a tea strainer submerged in
100 ml of phosphate-buffered saline (PBS) maintained for 3 h at 37C in a
water bath. The L4 falling to the bottom of the beaker containing the PBS
were then placed in a line-grated rectangular culture dish and counted
using a dissecting microscope; larvae were identified morphologically as
L4 [40]. These mice were also inoculated with infective Heligmosomoides
polygyrus bakeri third-stage larvae and infective Trichuris muris eggs to
test Cry5B IBaCC efficacy against multiple nematode infections in a
single mouse host. The results of IBaCC treatment on these other para
sites will be presented in a separate report.

3. Results
3.1. Cry5B IBaCC intoxicates A. suum intestinal fourth larval stage in
vitro
Bt Cry5B is a potent anthelmintic protein that has been studied in vivo
against hookworms in rodents/dogs and Ascaris infections in pigs
delivered as spore crystal lysates or as protein isolated from spore crystal
lysates, neither of which are compatible with scale up technologies or
broadly effective drug distribution strategies [31,33,42–46]. IBaCC or
Inactivated Bacterium with Cytosolic Crystal is an API form compatible
with MDA in which Bt Cry protein crystals are produced in the cytosol of
asporagenous Bt, that is subsequently killed or inactivated by incubation
in food-grade essential oil [31]. IBaCC is effective against hookworm
infections in rodents and Haemonchus infections in ruminants (Li et al.
2020; Sanders et al. 2020). A dead probiotic with therapeutic benefit is
known as a paraprobiotic [37].
How IBaCC would interact with ascarids, which have different
mouth parts, feeding patterns, food sources, and behaviors than hook
worms, was unknown. IBaCC containing Cry5B (or Cry5B IBaCC) was
initially tested against intestinal A. suum fourth stage larvae (L4s) using
a new protocol for isolation from immune deficient mice and incubated
in vitro with IBaCC containing two different Cry5B doses. Visible changes
in the L4 treated with Cry5B IBaCC relative to buffer control were seen
(e.g., paler coloration, degenerated intestinal appearance, rigidity in
shape, and reduced movement), indicating clear intoxication of A. suum
by Cry5B IBaCC (Fig. 1A). Intoxication was quantitatively evident at 10
μg/mL and more strongly at 100 μg/mL Cry5B content, with near
complete death/immobilization seen at 100 μg/mL (~700 nmolar) at
48 h (Fig. 1B). As has been shown with all other parasitic nematodes
tested [31,47], intoxication of A. suum by Cry5B IBaCC was dependent
upon Cry5B protein since incubation of parasites in the presence of IBa
control lacking Cry5B but otherwise identical to IBaCC resulted in no
intoxication (detailed in Materials and Methods). These in vitro data
indicated that Cry5B IBaCC, but not the inactivated bacterium
B. thuringiensis with empty vector (IBa), has potential to impact A. suum
infections in vivo.

2.4. Pig Ascaris in vivo experiment
Experimental pigs were obtained from the facility at the Beltsville
Agricultural Research Center, Beltsville, MD and were housed and
managed as previously described [33]. The pigs were mixed sex and
approximately 8 weeks of age with each group containing six pigs at the
time of per os inoculation with 10,000 infective A. suum eggs [33]. Pigs
were treated per os 12 days after parasite egg inoculation with a single
dose of IBaCC at 30 mg/kg Cry5B body weight (treated group) or a
vehicle control (control group) and euthanized four days later to recover
A. suum L4 from the small intestine [33]. The L4 isolated from an agargel matrix of intestinal contents were counted using a dissecting mi
croscope to determine the number of morphologically identified L4 [40]
per pig.
2.5. Horse Parascaris spp. experiment
Ten horse foals born on the University of Kentucky Research Farm in
2019 were enrolled in the study. The foals were exposed to parasites on
contaminated pasture to become naturally infected with Parascaris spp.
and did not receive anthelmintic treatment prior to the study. From
three months of age, the foals were examined for ascarid fecal egg counts
determined in triplicate with the Mini-FLOTAC method as previously
described [41] . Once foals exceeded 100 ascarid eggs per gram (EPG),
they were ranked by egg count magnitude and blocked into pairs of two.
From these blocks, foals were randomly allocated to either treatment or
control group. Foals in the treatment group were administered a single
dose of Cry5B IBaCC at 30 mg/kg via nasogastric tube. Foals in the
control group were kept untreated. Egg counts were determined on the
day of treatment and weekly for four weeks post treatment.

3.2. Cry5B IBaCC has a significant impact on intestinal A. suum intestinal
infections in mice and pigs
Before testing in large animals, we tested Cry5B IBaCC against in
testinal A. suum infections in mice. We have found that C57BL/6(B6)STAT6KO mice support the development of A. suum to the L4 intesti
nal stage, at which point they are expelled (~day 20 post-inoculation or
P.I.). B6/STAT6KO mice were inoculated per os with A. suum eggs.
Twelve days P.I., the mice (n = 5 per group) were treated with either
water (control), IBaCC at 6 mg Cry5B/kg by body weight, or IBaCC at 20
mg Cry5B/kg body weight. Those mice that received 20 mg/kg received
a second 20 mg/kg body weight dose day 13 P.I. This double 20 mg/kg
dose mimics what was done in the published pig study using Cry5B SCL
[33]. Five days later small intestinal worm burdens were determined.
Treatment with two 20 mg/kg doses resulted in a statistically significant
92.5% reduction in intestinal worm burdens relative to control (Fig. 2),
similar to what was seen in pigs using SCL and the same dosing regimen
[33]. Treatment using a single 6 mg/kg body weight of Cry5B in IBaCC
also resulted in a significant 62% reduction in intestinal A. suum L4
burdens (Fig. 2). These results in mice with a TH2-immune deficient
background further reinforce previous findings that Cry5B efficacy is
due to a direct impact on parasites and is not dependent upon an intact
immune response [44].
Based on in vitro data and in vivo efficacy in the mouse model, Cry5B
IBaCC production was scaled up to 350 l at a contract manufacturing
organization (CMO) for studies in large animals [31]. Twelve pigs were
inoculated per os with A. suum eggs. Based on success with single dosing
in mice, a single-dose treatment trial was performed. Twelve days P.I.,

2.6. Statistical methods
Prism v.8 was used for all graphs and comparisons. The comparison
of fecal egg counts in the foal study was carried out using two-way
analysis of variance (mixed-effects analysis Time x Treatment). For the
in vivo mouse experiment, one-way analysis of variance (ANOVA) with
Dunnett’s post-test was used relative to water control. For comparisons
including just two groups in the pig study and the end of the horse study,
a one-tailed Mann-Whitney (non-parametric) test was used with the
assumption that treatment reduced parasite burdens or fecal egg counts.
For the comparison of fecal egg counts at the beginning of the horse
study, a two-tailed Mann-Whitney test was used to test for equivalence
of starting fecal egg counts.
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Fig. 1. Cry5B IBaCC intoxicates A. suum in vitro. A)
Image of A. suum fourth-stage larvae (L4) in the pres
ence of 100 μg/mL Cry5B in IBaCC or absence of Cry5B
IBaCC. Intoxicated larvae were straightened and
immobile. Healthy larvae had multiple bends and were
motile. Images were taken at 48 h. B) Percent of
A. suum larvae alive over time in vitro at two doses of
Cry5B in IBaCC relative to control (buffer only). Shown
is the average and standard error of two independent
experiments with two wells per experiment (5 larvae
per well).

3.3. Cry5B IBaCC clears fecal egg counts in horses infected with the
related parasite Parascaris spp
Parascaris infection is deleterious to equines (foals) and is phyloge
netically related to A. suum and A. lumbricoides [48,49]. As scaled-up
IBaCC effectively cleared A. suum infections in pigs at a single dose of
30 mg Cry5B/kg body weight, we similarly tested a single dose of IBaCC
at 30 mg Cry5B/kg body weight against adult Parascaris spp. infections
in naturally infected foals.
Ten foals were selected via rolling enrollment in control (n = 4) and
Cry5B IBaCC treatment arms (n = 6). Each foal in the treatment arm was
administered via naso-gastric tube a single dose of 30 mg/kg Cry5B in
IBaCC produced at 350 l scale by a CMO. Fecal egg counts were deter
mined on the day of treatment and then once weekly for 4 weeks. The
results are shown in Fig. 4. Fecal egg counts in foals from both the
control and treatment arms were statistically similar at the beginning of
the study, with mean ascarid egg counts of 916 and 673 eggs per gram of
feces, respectively. Fecal egg counts persisted in all foals in the control
group up until and including day 14 and in three out of four foals
throughout the entire duration of the study. In contrast, fecal egg counts
went to zero in all Cry5B IBaCC-treated foals at the first sample taken
one-week post-treatment and stayed at zero for all treated foals
throughout the study. Two-way analysis of variance showed a statisti
cally significant difference between control and treatment arms. A sig
nificant difference in fecal egg counts at each time point post-treatment
was also seen (shown for the final time point; Fig. 4). These data indi
cated that Cry5B IBaCC had a dramatic impact on Parascaris infections in
foals.

Fig. 2. Cry5B IBaCC is efficacious against A. suum L4 intestinal stage in mice.
Shown are the parasite burdens from B6/STAT6KO mice inoculated with
infective A. suum eggs and treated with water, single dose Cry5B IBaCC (6 mg/
kg body weight), or double dose Cry5B IBaCC (2 × 20 mg/kg body weight).
Statistical comparisons of treated groups relative to water control are shown.
Long bar for each treatment is mean; short bars indicate standard error.

six pigs were left untreated and six pigs were given per os a single dose of
IBaCC at a dose of 30 mg Cry5B/kg body weight. Four days later, in
testinal worm counts were determined for all pigs. As shown (Fig. 3),
single dose Cry5B IBaCC resulted in a statistically significant reduction
and near complete clearance of A. suum L4 from the pig intestine (96%
reduction relative to control).

4. Discussion
Ascarid parasites are some of the most common and damaging

Fig. 4. Cry5B IBaCC is highly effective against Parascaris spp. Infections in
foals. Shown are the average fecal egg counts over time; error bars indicate
standard error. Day 0 fecal egg counts were taken before the first treatment. The
difference between fecal egg counts between control and foals treated with
IBaCC at 30 mg/kg Cry5B body weight based on two-way analysis of variance
was significant (P = 0.0074). P values shown indicate the comparison between
fecal egg counts in treated and control groups before treatment (day 0; P =
0.91) and at the last data point taken (day 28; P = 0.033).

Fig. 3. Cry5B IBaCC is highly effective against A. suum L4 intestinal stage in
fections in pigs. Shown are the average parasite burdens in pigs given water or
single dose Cry5B IBaCC at 30 mg/kg body weight. Error bars indicate stan
dard error.
4
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parasites of humans and animals on earth. In veterinary medicine, the
recalcitrance of Parascaris to treatment and development to resistance is
well documented. Although Ascaris infections in humans are considered
well managed with current therapeutics, a detailed look at the efficacy
data and the propensity for livestock to develop anthelmintic resistance
from intensive drug treatment is foreboding for MDA strategies in
humans (see Introduction). Therefore, new therapies against this class of
parasite in the pipeline are urgently needed and would play an impor
tant role in promoting One Health. However, to be therapeutically
deployable in both human and veterinary medicine in the developed and
developing world, such therapies need to be safe, broadly active against
this class of parasite, inexpensive, and massively scalable. We are un
aware of any new drugs that meet these criteria that are in the com
mercial pipeline.
Here we demonstrated that Cry5B IBaCC, a recombinant parapro
biotic (dead bacterial ghost) containing an active Bt Cry protein crystal,
has great promise to fulfill this void. Single-dose Cry5B IBaCC is effective
against two ascarid species in vivo in three different mammalian hosts. In
mice and pigs, Cry5B IBaCC was effective at near complete elimination
of A. suum parasite burdens in the small intestine. In horses, Cry5B
IBaCC completely eliminated parasite fecal egg counts. Important future
studies in horses would include determination of intestinal parasite
burdens in control versus Cry5B IBaCC-treated foals. Because A. suum
and A. lumbricoides are very closely related parasites and because the pig
GI tract is considered a good model for the human GI tract, the data
suggest that Cry5B IBaCC will be highly effective against A. lumbricoides
infections in humans. Important future studies would also include
testing this hypothesis.
Cry5B IBaCC production was scaled up for these large animal studies
to 350 l scale at a CMO. Crystal proteins as part of live spore crystal
lysates are massively and cheaply produced around the world to control
insect pests, paving the way for comparable production levels of Cry5B
IBaCC. However, the therapeutic application of live spore crystal lysates
or live bacteria in general is not desirable for humans and other animals
because of potential safety issues, environmental contamination, repli
cation in soil and intestines leading to increased risk of parasite resis
tance, instability of live bacteria on the shelf, and the relationship
between B. thuringiensis and Bacillus cereus [31]. Cry5B IBaCC alleviates
all these disadvantages while retaining all the advantages of scalability
and safety of Cry proteins themselves. The production process of Cry5B
IBaCC itself is simple and transferable [31]. Moreover, a pilot toxicology
study in hamsters demonstrated that five consecutive daily doses of
IBaCC at 200 mg Cry5B/kg body weight was completely safe and nontoxic based on no deviation from normal histopathology and blood
chemistry [31]. Good laboratory practice (GLP) toxicological studies
with larger-sized study groups and clinical-grade materials are planned
for the near future.
Notably, the development of anthelmintic resistance to Cry5B was
found to be relatively more difficult than to a benzimidazole and a
nicotinic acetylcholine receptor (nAChR) agonist based on forward ge
netic screens in Caenorhabditis elegans [50]. Furthermore, nematodes
resistant to nAChR agonist anthelmintics were hyper-susceptible to
Cry5B, and Cry5B and nAChR agonists (e.g., pyrantel and tribendimi
dine) were synergistically more efficacious in vitro and in vivo against
free-living and parasitic nematodes [43,50]. These properties (hypersusceptibility and synergy) are predictive of combination drug therapies
recalcitrant to the development of resistance.

generally points towards the suitability and great potential of parapro
biotics to treat pathogens of humans and livestock, that is also likely to
include ascarids of companion animals such as dogs and cats. Devel
opment of a common delivery system of paraprobiotic formulations for
cures for both humans and animals promotes the concept of One Health.
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